Updates

October 22, 2020October 22, 2020
FDA Approves Venclexta Combinations for Newly Diagnosed AML

The U.S. Food and Drug Administration (FDA) has granted full approval to Venclexta (venetoclax), in combination with Vidaza (azacitidine), Dacogen (decitabine), or low-dose cytarabine, ... Read more
October 19, 2020October 19, 2020
Telehealth ‘Helpful’ Alternative to In-person Care, Rare Disease Patients Say

A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like the option of continuing its ... Read more
October 15, 2020October 15, 2020
Omidubicel Shows Further Trial Benefits for Marrow Transplants in AML, Other Cancers

Omidubicel, an experimental cell therapy for blood cancer patients needing a bone marrow transplant, is superior to standard umbilical cord blood transplant at increasing the proportion of ... Read more
October 12, 2020October 12, 2020
TXNIP Protein Deficiency Linked to Poor Prognosis for AML Patients, Study Finds

Low expression levels of the protein TXNIP — thioredoxin interacting protein — was associated with worse outcomes in people with acute myeloid leukemia (AML), ... Read more
October 8, 2020October 8, 2020
Phase 1 Trial Finishes Dosing 1st AML Patient Group With Actimab-A Plus Venclexta

The first group of patients with relapsed or refractory acute myeloid leukemia (AML) has been dosed in a Phase 1/2 dose-escalation trial assessing the ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

Pin It on Pinterest